StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Up 74.1 %
NASDAQ:PULM opened at $3.57 on Friday. The company has a market capitalization of $13.04 million, a P/E ratio of -1.35 and a beta of 0.99. The firm has a 50-day moving average price of $2.10 and a two-hundred day moving average price of $2.04. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $4.12.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative return on equity of 45.97% and a negative net margin of 96.51%. The business had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- 3 Best Fintech Stocks for a Portfolio Boost
- Rocket Lab is the Right Stock for the Right Time
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- How to Calculate Return on Investment (ROI)
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
